Selection of Patients with Resistant Arterial Hypertension for the Catheter-Based Renal Sympathetic Denervation

Purpose: elaboration of algorithm for selection of patients with resistant arterial hypertension (AH) for Catheter-Based Renal Sympathetic Denervation (CBRSD). Materials and methods. We examined 284 patients with resistant AH. On stage 1 we excluded most frequent causes of secondary AH. In 247 patients (86.9 %) we established secondary character of AH, in 37 patients (13.1 %) AH was found to be essential. On stage 2 patients with essential AH were given 3–5 component hypotensive therapy. At the background of this therapy we conducted 24‑hour ambulatory blood pressure monitoring (ABPM). CBRSD procedure was considered indicated if according to ABPM average 24‑hour blood pressure (BP) was above 150 and 100 mm Hg, and 24‑hour elevated BP load exceeded 60 %. In 13 of 37 patients (35 %) BP level satisfied these conditions. For CBRSD we used high frequency generator. Ablation was performed using the Symplicity Catheter. Results were assessed in 1, 2, 9, 12, and 28 months. Results.Target BP level at the background of minimal doses of hypotensive drugs was achieved in 11 patients (85 %), what was confirmed by ABPM data. Levels of mean 24–4 hour systolic and diastolic BP significantly decreased from 173.9±14.9 to 143±21.3, р<0.05, and from 108.2±8.7 to 91.4±13.8 mm Hg., р<0.05, respectively. Index of elevated systolic BP time decreased from 78.2±14.6 to 49.8±29.6 %, р<0.05. Best effect was achieved in patients with AH duration before the procedure less than 7 years. None of the patients had episodes of cerebral vascular insufficiency or heart failure progression. Conclusion. While determining indications to bilateral CBRSD one should be governed by such criteria as exclusion of symptomatic AH and objective proofs of AH resistance (according to ABPM at the background of hypotensive therapy). 

1. Shlyakhto E. V. The resistant arterial hypertension. -St. Petersburg: Studio NP-Print; 2012. - 117p. ISBN 978-5-91542-147-8

2. Messerli FH, Bangalore S. Treatment-resistant hypertension: another Cinderella story. European Heart Journal. 2013;34(16):1175-7. https://doi.org/10.1093/eurheartj/eht028

3. Ripp T. M., Mordovin V. F. Renal denervation: view of cardiologist. Cardiology: news, views, education. 2017;2(13):31-8.

4. Moser M, Setaro JF. Resistant or Difficult-to-Control Hypertension. New England Jour-nal of Medicine. 2006;355(4):385-92. https://doi.org/10.1056/NEJMcp041698

5. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systol-ic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265(24):3255-64. PMID: 2046107

6. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH et al. Success and predictors of blood pressure control in diverse North American settings: the antihy-pertensive and lipidlowering treatment to prevent heart attack trial (ALLHAT). Journal of Clinical Hypertension (Greenwich, Conn.). 2002;4(6):393-404. PMID: 12461301

7. Chazova I. E., Fomin V. V., Razuvaeva M. A., Vigdorchik A. V. Resistant and un-controlled essential hypertension in Russian Federation: epidemiological characteristics and treatment approaches. Russian register of uncontrolled and resistant hypertension REHATA “REsistant Hypertension ArTeriAl”. Kardiologicheskii vestnik. 2011;6(1):40-8.

8. Pierdomenico SD, Lapenna D, Di Tommaso R, Di Carlo S, Esposito AL, Di Mascio R et al. Cardiovascular risk in patients receiving double therapy with false and true nonre-sponder hypertension: Blood Pressure Monitoring. 2006;11(6):303-7. https://doi.org/10.1097/01.mbp.0000218008.65580.5d

9. Bakris G, Nathan S. Renal Denervation and Left Ventricular Mass Regression. Journal of the American College of Cardiology. 2014;63(18):1924-5. https://doi.org/10.1016/j.jacc.2013.11.015

10. Bhatt DL, Bakris GL. The promise of renal denervation. Cleveland Clinic Journal of Medicine. 2012;79(7):498-500. https://doi.org/10.3949/ccjm.79a.12051

11. Thukkani AK, Bhatt DL. Renal Denervation Therapy for Hypertension. Circulation. 2013;128(20):2251-4. https://doi.org/10.1161/CIRCULATIONAHA.113.004660

12. Myat A, Redwood SR, Qureshi AC, Thackray S, Cleland JGF, Bhatt DL et al. Renal Sympathetic Denervation Therapy for Resistant Hypertension: A Contemporary Synop-sis and Future Implications. Circulation: Cardiovascular Interventions. 2013;6(2):184-97. https://doi.org/10.1161/CIRCINTERVENTIONS.112.000037

13. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. The Lancet. 2009;373(9671):1275-81. https://doi.org/10.1016/S0140-6736(09)60566-3

14. Elser MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympa-thetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. The Lancet. 2010;376(9756):1903-9. https://doi.org/10.1016/S0140-6736(10)62039-9

15. Renal sympathetic denervation in patients with treatment-resistant hypertension: the re-sults of trial SYMPLICITY HTN-3. Evidence-based cardiology. 2014;2:4-9.

16. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT et al. A Controlled Trial of Renal Denervation for Resistant Hypertension. New England Journal of Medicine. 2014;370(15):1393-401. https://doi.org/10.1056/NEJMoa1402670

17. Papademetriou V, Tsioufis C, Doumas M. Renal Denervation and Symplicity HTN-3: “Dubium Sapientiae Initium” (Doubt Is the Beginning of Wisdom). Circulation Re-search. 2014;115(2):211-4. https://doi.org/10.1161/CIRCRESAHA.115.304099

18. Ripp TM, Mordovin VF, Pekarskiy SE, Ryabova TR, Zlobina MV, Baev AE et al. Pre-dictors of Renal Denervation Efficacy in the Treatment of Resistant Hypertension. Cur-rent Hypertension Reports. 2015;17(12):90. https://doi.org/10.1007/s11906-015-0603-8

19. Pekarskiy SE, Baev AE, Mordovin VF, Semke GV, Ripp TM, Falkovskaya AU et al. Denervation of the distal renal arterial branches vs. conventional main renal artery treat-ment: a randomized controlled trial for treatment of resistant hypertension. Journal of Hypertension. 2017;35(2):369-75. https://doi.org/10.1097/HJH.0000000000001160

20. Jaff MR, Bass TA. Competent care through the lens of the vascular patient: Next steps in quality. Catheterization and Cardiovascular Interventions. 2014;83(2):169-70. https://doi.org/10.1002/ccd.25217

21. Ripp TM, Rebrova TY, Mordovin VF, Afanasiev SA, Pekarsky SE, Semke GV et al. Criteria for selecting patients with resistant hypertension for a renal sympathetic denerva-tion. Therapeutic Archive. 2016;88(8):14-8. https://doi.org/10.17116/terarkh201688814-18

22. Poulter NR, Wedel H, Dahlöf B, Sever PS, Beevers DG, Caulfield M et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (AS-COT-BPLA). The Lancet. 2005;366(9489):907-13. https://doi.org/10.1016/S0140-6736(05)67186-3